A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen
Jeroen J W M
JJ
Department of Hematology, VU University Medical Center, HV Amsterdam, The Netherlands. jjwm.janssen@vumc.nl
Berendse
Henk W
HW
Schuurhuis
Gerrit-Jan
GJ
Merle
Pauline A
PA
Ossenkoppele
Gert J
GJ
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001037:Aphasia / Q000209:etiology*; D001259:Ataxia / Q000209:etiology*; D001549:Benzamides; D001752:Blast Crisis / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D003221:Confusion / Q000209:etiology*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D034381:Hearing Loss / Q000209:etiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate